Grant: CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Ottawa Hospital Research Institute
$64,688.00
Defining the role of Sox9 in tumor progression and stem cell function in HER2-driven breast cancers
FY 2023-24
Summary
HER2 is over-expressed or amplified in 25-30% of breast cancers and has been implicated in highly metastatic breast cancers. The Sox9 and Sox10 proteins binds DNA and regulates multiple genes associated with mammary stem cell activity and function. High Sox9 expression is associated with a worse outcome, suggesting that Sox9+/HER2+ tumors represent a more aggressive stem-like subtype. We have found that Sox10 deletion in a HER2+ mouse model completely abrogates tumor formation while still expressing Sox9, suggesting that it can’t compensate for Sox10. This proposal will assess the role of Sox9 in tumor stem cell function and metastasis of HER2+ cancers. We will identify Sox9-regulated genes for therapeutic targeting. Our studies should identify novel therapeutic avenues for the ablation cancer stem cells in breast cancers.
Department
Program
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Recipient
Location
Ontario, Canada
Recipient Type
Other
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
517001
Name
Sabourin Luc A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Defining the role of Sox9 in tumor progression and stem cell function in HER2-driven breast cancers
Programtype2
Operating Grants
Orgnameinp2
Ottawa Hospital Research Institute
Cihramount2
$64,688
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Keyworddelim
Breast Cancer
Abstract
HER2 is over-expressed or amplified in 25-30% of breast cancers and has been implicated in highly metastatic breast cancers. The Sox9 and Sox10 proteins binds DNA and regulates multiple genes associated with mammary stem cell activity and function. High Sox9 expression is associated with a worse outcome, suggesting that Sox9+/HER2+ tumors represent a more aggressive stem-like subtype. We have found that Sox10 deletion in a HER2+ mouse model completely abrogates tumor formation while still expressing Sox9, suggesting that it can’t compensate for Sox10. This proposal will assess the role of Sox9 in tumor stem cell function and metastasis of HER2+ cancers. We will identify Sox9-regulated genes for therapeutic targeting. Our studies should identify novel therapeutic avenues for the ablation cancer stem cells in breast cancers.
Competitiondate
202402
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Sabourin, Luc A
Approvedterm
2 ans 0 mois
Cihrcontribution2
ICR~ $64,688~ $0~
